BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1354 related articles for article (PubMed ID: 33201207)

  • 21. [Intravesical therapy of non-muscle invasive bladder tumors].
    Vom Dorp F; Tschirdewahn S; Lümmen G
    Urologe A; 2012 Feb; 51(2):257-64. PubMed ID: 22331075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparison of the effectiveness between long-term instillation of mitomycin C and short-term prophylaxis with MMC or bacille Calmette-Guérin. Study of patients with non-muscle-invasive urothelial cancer of the urinary bladder].
    Isbarn H; Budäus L; Pichlmeier U; Conrad S; Huland H; Friedrich MG
    Urologe A; 2008 May; 47(5):608-15. PubMed ID: 18317718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
    Lamm D; Brausi M; O'Donnell MA; Witjes JA
    Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update on intravesical agents for non-muscle-invasive bladder cancer.
    Shariat SF; Chade DC; Karakiewicz PI; Scherr DS; Dalbagni G
    Immunotherapy; 2010 May; 2(3):381-92. PubMed ID: 20635902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
    Turker P; Turkeri L
    Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer.
    Monteiro LL; Witjes JA; Agarwal PK; Anderson CB; Bivalacqua TJ; Bochner BH; Boormans JL; Chang SS; Domínguez-Escrig JL; McKiernan JM; Dinney C; Godoy G; Kulkarni GS; Mariappan P; O'Donnell MA; Rentsch CA; Shah JB; Solsona E; Svatek RS; van der Heijden AG; van Valenberg FJP; Kassouf W
    World J Urol; 2019 Jan; 37(1):51-60. PubMed ID: 30109483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Failure of bacille Calmette-Guérin in patients with high risk non-muscle-invasive bladder cancer unsuitable for radical cystectomy: an update of available treatment options.
    Yates DR; Rouprêt M
    BJU Int; 2010 Jul; 106(2):162-7. PubMed ID: 20201829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic anti-CTLA-4 and intravesical Bacille-Calmette-Guerin therapy in non-muscle invasive bladder cancer: Is there a rationale of synergism?
    Fahmy O; Khairul-Asri MG; Stenzl A; Gakis G
    Med Hypotheses; 2016 Jul; 92():57-8. PubMed ID: 27241256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bladder-preserving strategies for Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected?
    Sari Motlagh R; Pradere B; Mori K; Miura N; Abufaraj M; Shariat SF
    Curr Opin Urol; 2020 Jul; 30(4):584-593. PubMed ID: 32304379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.
    Luciani LG; Neulander E; Murphy WM; Wajsman Z
    Urology; 2001 Sep; 58(3):376-9. PubMed ID: 11549484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-Risk Non-Muscle-Invasive Bladder Cancer-Therapy Options During Intravesical BCG Shortage.
    Veeratterapillay R; Heer R; Johnson MI; Persad R; Bach C
    Curr Urol Rep; 2016 Sep; 17(9):68. PubMed ID: 27492610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor.
    Huang B; Huang G; Li W; Chen L; Mao X; Chen J
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1781-1788. PubMed ID: 33222014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
    Shepherd AR; Shepherd E; Brook NR
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
    Steinbach F; Schuster F
    Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
    Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
    Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bladder Cancer: Diagnosis and Treatment.
    DeGeorge KC; Holt HR; Hodges SC
    Am Fam Physician; 2017 Oct; 96(8):507-514. PubMed ID: 29094888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
    Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guérin immunotherapy?
    Golabek T; Palou J; Rodríguez O; Gaya JM; Breda A; Villavicencio H
    World J Urol; 2017 Feb; 35(2):237-243. PubMed ID: 27277599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer.
    Rao MV; Ellimoottil C; Sondej T; Flanigan RC; Quek ML
    Urol Oncol; 2013 Aug; 31(6):857-61. PubMed ID: 21868262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 68.